Encapsidating artificial human papillomavirus-16 mE7 protein in human papillomavirus-6b L1/L2 virus like particles

Chinese Medical Journal

Volumn 120, Issue 6, 2007, Pages 503-508

  Xu, Yu Fei ^a   Wang, Qing Yong ^a   Zhang, Hong Tao ^b   Han, Ye Hua ^a   Song, Gou Xing ^a   Xu, Xue Mei ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^b NEW YORK BLOOD CENTER   (United States)

Author keywords

Cervical cancer; Chimeric virus like particles; Human papillomavirus; Vaccine

Indexed keywords

CAPSID PROTEIN; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; POLYCLONAL ANTIBODY; PROTEIN E7;

ANIMAL CELL; ANTIGEN RECOGNITION; ARTICLE; CODON; CONTROLLED STUDY; DNA SHUFFLING; ELECTRON MICROSCOPY; GENE INSERTION; GENE SYNTHESIS; HEMAGGLUTINATION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 6; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOGENICITY; INSECT CELL; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; POINT MUTATION; PROTEIN ASSEMBLY; PROTEIN EXPRESSION; ULTRACENTRIFUGATION; VIRUS LIKE AGENT;

EID: 34047130697     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200703020-00013     Document Type: Article

References (24)

1. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. Epidemiological classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518-527.
2. Schiller JT, Davies P. Delivering on the promise: HPV vaccines and cervical cancer. Nat Rev Microbiol 2004; 2: 343-347.
3. von Knebel DM, Rittmuller C, zur HH, Durst M. Inhibition of tumorigenicity of cervical cancer cells in nude mice by HPV E6-E7 antisense RNA. Int J Cancer 1992; 51: 831-834.
4. Jochmus I, Schafer K, Faath S, Muller M, Gissmann L. Chimeric virus like particles of the human papillomavirus type 16 (HPV-16) as a prophylactic and therapeutic vaccine. Arch Med Res 1999; 30: 269-274.
5. Xu YF, Zhang YQ, Xu XM, Song GX. Papillomavirus virus like particles as vehicles for the delivery of epitopes or genes. Arch Virol 2006; 151: 2133-2148.
6. Wang M, Wang LL, Chen LF, Han YH, Zou YH, Si JY, et al. Expression of human papillomavirus type 6 L1 and L2 isolated in China and self assembly of virus like particles by the products. Acta Biochim Biophys Sin 2003; 35: 27-34.
7. Xu XM, Xu YF, Wang QY, Song GX, Zeng Y, Si JY. Development of human papillomavirus type 16 DNA vaccine and gene adjuvants: China, 200610079644.X.
8. Shi W, Liu J, Huang Y, Qiao L. Papillomavirus pseudovirus: a novel vaccine to induce mucosal and systemic cytotoxic T-lymphocyte responses. J Virol 2001; 75: 10139-10148.
9. Christensen ND, Reed CA, Cladel NM, Hall K, Leiserowitz GS. Monoclonal antibodies to HPV-6 L1 virus like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to type specific epitopes on HPV-6. Virology 1996; 224: 477-486.
10. Roden RB, Hubbert NL, Kirnbauer R, Breitburd F, Lowy DR, Schiller JT. Papillomavirus L1 capsids agglutinate mouse erythrocytes through a proteinaceous receptor. J Virol 1995; 69: 5147-5151.
11. Collier B, Oberg D, Zhao X, Schwartz S. Specific inactivation of inhibitory sequences in the 5′ end of the human papillomavirus type 16 L1 open reading frame results in production of high levels of L1 protein in human epithelial cells. J Virol 2002; 76: 2739-2752.
12. Rollman E, Arnheim L, Collier B, Oberg D, Hall H, Klingstrom J, et al. HPV-16 L1 genes with inactivated negative RNA elements induce potent immune responses. Virology 2004; 322: 182-189.
13. Cook JC, Joyce JG, George HA, Schultz LD, Hurni WM, Jansen KU, et al. Purification of virus like particles of recombinant human papillomavirus type 11 major capsid protein L1 from Saccharomyces cerevisiae. Protein Expr Purif 1999; 17: 477-484.
14. Greenstone HL, Nieland JD, de Visser KE, De Bruijn ML, Kirnbauer R, Roden RB, et al. Chimeric papillomavirus virus like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc Natl Acad Sci USA 1998; 95: 1800-1805.
15. Kirnbauer R, Taub J, Greenstone H, Roden R, Durst M, Gissmann L, et al. Efficient self assembly of human papillomavirus type 16 L1 and L1-L2 into virus like particles. J Virol 1993; 67: 6929-6936.
16. Multer M, Zhou J, Reed TD, Rittmuller C, Burger A, Gabelsberger J, et al. Chimeric papillomavirus like particles. Virology 1997; 234: 93-111.
17. Slupetzky K, Shafti-Keramat S, Lenz P, Brandt S, Grassauer A, Sara M, et al. Chimeric papillomavirus like particles expressing a foreign epitope on capsid surface loops. J Gen Virol 2001; 82(Pt 11): 2799-2804.
18. Wakabayashi MT, Da Silva DM, Potkul RK, Kast WM. Comparison of human papillomavirus type 16 L1 chimeric virus like particles versus L1/L2 chimeric virus like particles in tumor prevention. Intervirology 2002; 45: 300-307.
19. Osen W, Peiler T, Ohlschlager P, Caldeira S, Faath S, Michel N, et al. A DNA vaccine based on a shuffled E7 oncogene of the human papillomavirus type 16 (HPV-16) induces E7 specific cytotoxic T cells but lacks transforming activity. Vaccine 2001; 19: 4276-4286.
20. Ohlschlager P, Pes M, Osen W, Durst M, Schneider A, Gissmann L, et al. An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype specific T cell response. Vaccine 2006; 24: 2880-2893.
21. Brinkman JA, Xu XM, Kast WM. The Efficacy a DNA vaccine containing inserted and replicated regions of the E7 gene for treatment of HPV 16 induced tumors. Vaccine. In press 2007.
22. Muller M, Gissmann L, Cristiano RJ, Sun XY, Frazer IH, Jenson AB, et al. Papillomavirus capsid binding and uptake by cells from different tissues and species. J Virol 1995; 69: 948-954.
23. Volpers C, Unckell F, Schirmacher P, Streeck RE, Sapp M. Binding and internalization of human papillomavirus type 33 virus like particles by eukaryotic cells. J Virol 1995; 69: 3258-3264.
24. Da Silva DM, Pastrana DV, Schiller JT, Kast WM. Effect of preexisting neutralizing antibodies on the antitumor immune response induced by chimeric human papillomavirus virus like particle vaccines. Virology 2001; 290: 350-360.